Compare EXFY & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXFY | CUE |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | 117 | 29 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.9M | 124.5M |
| IPO Year | 2021 | 2017 |
| Metric | EXFY | CUE |
|---|---|---|
| Price | $1.15 | $29.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $4.50 | ★ $120.00 |
| AVG Volume (30 Days) | ★ 684.0K | 119.5K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,101,000.00 | $27,466,000.00 |
| Revenue This Year | $0.42 | N/A |
| Revenue Next Year | $0.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.06 | ★ 195.75 |
| 52 Week Low | $0.69 | $0.17 |
| 52 Week High | $2.55 | $41.42 |
| Indicator | EXFY | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 59.53 | 62.97 |
| Support Level | $0.77 | $0.30 |
| Resistance Level | $1.19 | $41.42 |
| Average True Range (ATR) | 0.03 | 2.91 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 50.00 | 80.56 |
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app. Small and medium-sized businesses (SMBs) are the cornerstone of the global economy, making up almost all businesses and the majority of employment in Organization for Economic Co-operation and Development (OECD) member countries.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.